Is Sonnet Biotherapeutics Stock a Good Investment?
Sonnet Biotherapeutics Investment Advice | SONN |
- Examine Sonnet Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sonnet Biotherapeutics' leadership team and their track record. Good management can help Sonnet Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sonnet Biotherapeutics' business and its evolving consumer preferences.
- Compare Sonnet Biotherapeutics' performance and market position to its competitors. Analyze how Sonnet Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Sonnet Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sonnet Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sonnet Biotherapeutics Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sonnet Biotherapeutics Holdings is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Sonnet Biotherapeutics Stock
Researching Sonnet Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.93. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonnet Biotherapeutics recorded a loss per share of 0.96. The entity last dividend was issued on the 2nd of April 2020. The firm had 1:8 split on the 30th of September 2024.
To determine if Sonnet Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sonnet Biotherapeutics' research are outlined below:
| Sonnet Biotherapeutics generated a negative expected return over the last 90 days | |
| Sonnet Biotherapeutics has high historical volatility and very poor performance | |
| Sonnet Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 147.81 K. Net Loss for the year was (18.83 M) with loss before overhead, payroll, taxes, and interest of (21.09 M). | |
| Sonnet Biotherapeutics Holdings currently holds about 5.22 M in cash with (21.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Sonnet Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Sonnet BioTherapeutics Releases Virtual Investor What this Means Segment |
Sonnet Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sonnet Biotherapeutics Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sonnet Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Sonnet Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sonnet Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | 0.14 | 0.07 | -0.07 | 50 | ||
2023-05-10 | 2023-03-31 | -0.49 | -0.34 | 0.15 | 30 | ||
2022-12-15 | 2022-09-30 | -1.51 | -1.67 | -0.16 | 10 | ||
2023-08-14 | 2023-06-30 | -0.31 | -0.13 | 0.18 | 58 | ||
2015-03-31 | 2014-12-31 | -0.14 | -0.4 | -0.26 | 185 | ||
2022-05-10 | 2022-03-31 | -1.68 | -1.96 | -0.28 | 16 | ||
2023-02-13 | 2022-12-31 | -1.1 | -0.8 | 0.3 | 27 | ||
2020-05-18 | 2020-03-31 | -0.32 | -0.86 | -0.54 | 168 |
Know Sonnet Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonnet Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonnet Biotherapeutics Holdings backward and forwards among themselves. Sonnet Biotherapeutics' institutional investor refers to the entity that pools money to purchase Sonnet Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citigroup Inc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 0.0 | Private Wealth Management Group Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 272 K | Sabby Management Llc | 2024-06-30 | 238.4 K | Virtu Financial Llc | 2024-06-30 | 32.7 K | Geode Capital Management, Llc | 2024-06-30 | 16.7 K | Tower Research Capital Llc | 2024-06-30 | 7.2 K | Ubs Group Ag | 2024-06-30 | 4 K | Blackrock Inc | 2024-06-30 | 520 | Bank Of America Corp | 2024-06-30 | 28.0 |
Sonnet Biotherapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.45 M.Market Cap |
|
Sonnet Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.63) | (1.72) | |
| Return On Capital Employed | (0.18) | (0.17) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.92) | (0.88) |
Determining Sonnet Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Sonnet Biotherapeutics is a good buy. For example, gross profit margin measures Sonnet Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sonnet Biotherapeutics' profitability and make more informed investment decisions.
Sonnet Biotherapeutics' Earnings Breakdown by Geography
Evaluate Sonnet Biotherapeutics' management efficiency
Sonnet Biotherapeutics has return on total asset (ROA) of (0.9693) % which means that it has lost $0.9693 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6457) %, meaning that it created substantial loss on money invested by shareholders. Sonnet Biotherapeutics' management efficiency ratios could be used to measure how well Sonnet Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -1.72. In addition to that, Return On Capital Employed is likely to grow to -0.17. At this time, Sonnet Biotherapeutics' Other Assets are very stable compared to the past year. As of the 22nd of November 2024, Net Tangible Assets is likely to grow to about 9 M, while Total Assets are likely to drop about 28.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 18.8 K | 34 K | |
| Tangible Book Value Per Share | -39.4 K | -37.5 K | |
| Enterprise Value Over EBITDA | (12.43) | (11.81) | |
| Price Book Value Ratio | 4.88 | 5.12 | |
| Enterprise Value Multiple | (12.43) | (11.81) | |
| Price Fair Value | 4.88 | 5.12 | |
| Enterprise Value | 46.1 M | 43.8 M |
Leadership effectiveness at Sonnet Biotherapeutics Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.045 |
Basic technical analysis of Sonnet Stock
As of the 22nd of November, Sonnet Biotherapeutics has the Coefficient Of Variation of (858.68), risk adjusted performance of (0.08), and Variance of 46.61. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sonnet Biotherapeutics, as well as the relationship between them.Sonnet Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonnet Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonnet Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonnet Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sonnet Biotherapeutics' Outstanding Corporate Bonds
Sonnet Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sonnet Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sonnet bonds can be classified according to their maturity, which is the date when Sonnet Biotherapeutics Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US835495AL63 Corp BondUS835495AL63 | View | |
| SON 18 01 FEB 25 Corp BondUS835495AM47 | View | |
| SON 225 01 FEB 27 Corp BondUS835495AN20 | View | |
| US835495AJ18 Corp BondUS835495AJ18 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Sonnet Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sonnet Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 2.2 | |||
| Mean Deviation | 4.76 | |||
| Coefficient Of Variation | (858.68) | |||
| Standard Deviation | 6.83 | |||
| Variance | 46.61 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.58) | |||
| Treynor Ratio | 2.19 | |||
| Maximum Drawdown | 37.58 | |||
| Value At Risk | (9.79) | |||
| Potential Upside | 12.31 | |||
| Skewness | 0.4418 | |||
| Kurtosis | 1.93 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 2.2 | |||
| Mean Deviation | 4.76 | |||
| Coefficient Of Variation | (858.68) | |||
| Standard Deviation | 6.83 | |||
| Variance | 46.61 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.58) | |||
| Treynor Ratio | 2.19 | |||
| Maximum Drawdown | 37.58 | |||
| Value At Risk | (9.79) | |||
| Potential Upside | 12.31 | |||
| Skewness | 0.4418 | |||
| Kurtosis | 1.93 |
Consider Sonnet Biotherapeutics' intraday indicators
Sonnet Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sonnet Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sonnet Biotherapeutics Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of November 2024 Other Reports | ViewVerify | |
| 4th of November 2024 Other Reports | ViewVerify | |
S1 | 28th of October 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Sonnet Stock media impact
Far too much social signal, news, headlines, and media speculation about Sonnet Biotherapeutics that are available to investors today. That information is available publicly through Sonnet media outlets and privately through word of mouth or via Sonnet internal channels. However, regardless of the origin, that massive amount of Sonnet data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sonnet Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sonnet Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sonnet Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sonnet Biotherapeutics alpha.
Sonnet Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sonnet Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sonnet Biotherapeutics Corporate Management
| Manuel Dafonseca | Head Operations | Profile | |
| Gael Hedou | Chief Officer | Profile | |
| John Cini | Chief CoFounder | Profile | |
| MD FACP | Chief Officer | Profile | |
| Jay Cross | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sonnet Biotherapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.